Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Impax

This page shows the latest Impax news and features for those working in and with pharma, biotech and healthcare.

CHMP recommends 19 new medicines for European approval

CHMP recommends 19 new medicines for European approval

Vertex Pharmaceuticals' Orkambi (lumacaftor/ivacaftor), a combination treatment for cystic fibrosis, also received a thumbs up, as did Impax's Parkinson's disease treatment Numient(levodopa/carbidopa).

Latest news

  • Pay-for-delay deals lead to inflated drug prices says study Pay-for-delay deals lead to inflated drug prices says study

    The model focuses on the period between the start of patent litigation between Shire and Barr (now part of Teva) and Impax in 2002/2003 and the launch of multiple generics

  • Chasing the cure for Parkinson's disease Chasing the cure for Parkinson's disease

    An extended-release capsule formulation of levodopa/carbidopa (IPX 066; Rytary; IMPAX Laboratories) has also been developed, and is awaiting approval in the US for the treatment of idiopathic Parkinson's.

  • GSK and Impax end Parkinson's collaboration GSK and Impax end Parkinson's collaboration

    Regulatory delays for IPX066 lead to split. GlaxoSmithKline (GSK) and Impax Pharmaceuticals have agreed to end their collaboration on the Parkinson's disease drug IPX066. ... noted. At the time, Dr Larry Hsu, president and CEO of Impax, said he was

  • Shire weathers generic Adderall XR challenge Shire weathers generic Adderall XR challenge

    Adderall XR sales are expected to continue to fall, however, with Impax due to launch its own generic version, pending FDA approval. ... Shire also faces a $48m payout to Impax to settle legal claims about its supply of generic Adderall XR.

  • Shire pays $48m to settle generic Adderall XR claims with Impax Shire pays $48m to settle generic Adderall XR claims with Impax

    Following Impax' legal claim, Shire filed a counterclaim against Impax related to its ordering practices. ... Impax also said it will continue with plans to launch its own version of Adderall XR, rather than Shire's authorised generic, pending FDA

More from news
Approximately 2 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Will biosimilars ever catch on in the US? Will biosimilars ever catch on in the US?

    The latest example involved Endo Pharmaceuticals paying Impax Laboratories $112m to delay selling a generic version of Opana ER.

  • Deal Watch October 2016 Deal Watch October 2016

    Lilly. AZD3293. $500 profit share. Neurology 2012. Impax US. Zomig US.

  • Deal Watch June 2016 Deal Watch June 2016

    The three deals with Mayne Pharma, Impax Laboratories and Dr Reddy's, for a combined value of over $1.5bn, cover portfolios of marketed and approved generic drugs, drugs currently pending ... acquisition assets. 652. Teva and Allergan/ Impax Laboratories.

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    847. Lineage Therapeutics/Impax Laboratories. Company acquisition. Includes generic and branded products such albendazole and epinephrine.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....

Quick links